A major scientific review was published Thursday, showing that drugs previously marketed as a breakthrough in combating Alzheimer's disease did not provide any tangible benefit to patients, but some experts criticized this study. This review collected data from 17 clinical trials, which included more than 20,000 people, and studied seven different anti-amyloid drugs, which accumulate in the brains of infected people, over a period of about 18 months. So why did this review question these drugs?

Published on: 04/16/2026 - 19:39

A scientific study published Thursday questioned the effectiveness of medications previously marketed as a major achievement in combating Alzheimer's disease, and considered that these medications do not lead to tangible improvement for patients, while experts criticized this study.

The review was conducted by Cochrane, which is considered a global reference in analyzing scientific evidence, and focused on drugs that target amyloid plaques that accumulate in the brains of people with this disease.

After decades of costly and fruitless research, the anti-amyloid drugs lecanimab and donanemab were considered a breakthrough, with hopes that they would slow the progression of the disease. However, concerns about their effectiveness, high cost, and side effects later prompted caution.

The Cochrane review collected data from 17 clinical trials that included more than 20,000 people, and studied seven different anti-amyloid drugs over a period of about 18 months.

The study's lead researcher, Francesco Nonino, said that early trials showed statistically significant differences, but they "did not translate into a meaningful clinical benefit for patients."

The researchers confirmed that brain imaging showed that the drugs actually succeeded in removing amyloid plaques, but study co-author Ido Richard said, "The idea that removing amyloid would benefit patients has been refuted."

On the other hand, British biologist John Hardy, the developer of the amyloid hypothesis, criticized these results, considering that the study collected data on effective medications alongside medications known to be ineffective, which “led to a reduction in the overall average results.”

Hardy told Agence France-Presse: “It is a naive study that should not have been published,” revealing that he worked as a consultant for the companies Eli Lilly, Biogen, and Eisai.

In response, Richard said that the drugs included in the study may work by different mechanisms, but they all target the same target, which is beta-amyloid proteins.

For his part, Australian neuroscientist Bryce Wessel said that the study “does not prove that amyloid plays no role in Alzheimer’s disease,” but it “shows that the current generation of anti-amyloid drugs does not live up to their promises.”

France 24/AFP

Keywords related to the article

The content you want to browse is no longer in service or is currently unavailable.